See more : Guangzhou R&F Properties Co., Ltd. (GZUHF) Income Statement Analysis – Financial Results
Complete financial analysis of Tiziana Life Sciences Ltd (TLSA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tiziana Life Sciences Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- NAOS Small Cap Opportunities Company Limited (NSC.AX) Income Statement Analysis – Financial Results
- Aurora Design Public Company Limited (AURA.BK) Income Statement Analysis – Financial Results
- Wing Tai Properties Limited (0369.HK) Income Statement Analysis – Financial Results
- St. Modwen Properties Limited (1IG.F) Income Statement Analysis – Financial Results
- LiveRamp Holdings, Inc. (RAMP) Income Statement Analysis – Financial Results
Tiziana Life Sciences Ltd (TLSA)
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K | 0.00 | -82.00K | 0.00 | 56.00K | 92.00K | 64.00K | 405.00K | 116.00K | 99.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.00K | 20.00K | 24.00K | 209.00K | 40.00K | 45.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.00K | 0.00 | -82.00K | 0.00 | 45.00K | 72.00K | 40.00K | 196.00K | 76.00K | 54.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 100.00% | 0.00% | 80.36% | 78.26% | 62.50% | 48.40% | 65.52% | 54.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 8.11M | 12.96M | 13.21M | 5.99M | 2.91M | 4.34M | 4.67M | 2.96M | 6.29M | 794.00K | 0.00 | 0.00 | 0.00 | 0.00 | 80.00K | 412.00K | 737.00K | 826.00K | 745.00K | 457.00K | 326.00K | 580.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 855.00K | 13.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 286.00K | 458.00K | 207.00K | 0.00 | 719.00K | 1.18M | 1.53M | 1.67M | 0.00 | 0.00 | 0.00 | 1.29M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 0.00 | 855.00K | 13.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 286.00K | 458.00K | 207.00K | 0.00 | 719.00K | 1.18M | 1.53M | 1.67M | 0.00 | 0.00 | 0.00 | 1.29M | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Expenses | 9.87M | 1.63M | 13.31M | 8.82M | 4.86M | 3.48M | 3.57M | 4.33M | 2.33M | 1.97M | 0.00 | 0.00 | 82.00K | -3.03M | -9.00K | -2.00K | 63.00K | 0.00 | 1.50M | 1.06M | 218.00K | 451.00K | 2.42M | 2.43M | 488.00K | 199.00K |
| Operating Expenses | 17.98M | 14.59M | 27.37M | 30.04M | 7.77M | 7.82M | 8.25M | 7.29M | 8.61M | 2.76M | 286.00K | 458.00K | 289.00K | -3.03M | 790.00K | 1.59M | 2.33M | 2.50M | 2.24M | 1.52M | 544.00K | 2.32M | 2.42M | 2.43M | 488.00K | 199.00K |
| Cost & Expenses | 17.98M | 14.59M | 27.37M | 28.03M | 7.77M | 7.82M | 8.25M | 7.29M | 8.61M | 2.76M | 286.00K | 458.00K | 289.00K | -3.03M | 801.00K | 1.61M | 2.35M | 2.71M | 2.28M | 1.57M | 544.00K | 2.32M | 2.42M | 2.43M | 488.00K | 199.00K |
| Interest Income | 1.15M | 0.00 | 0.00 | 8.00K | 1.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.00K | 56.00K | 36.00K | 47.00K | 47.00K | 10.00K | 22.00K | 79.00K | 157.00K | 8.00K | 1.00K |
| Interest Expense | 10.00K | 7.00K | 176.00K | 320.00K | 73.00K | 9.46K | 9.00K | 9.00K | 18.00K | 14.00K | 0.00 | 0.00 | 0.00 | 0.00 | 4.00K | 3.00K | 5.00K | 8.00K | 10.00K | 5.00K | 8.00K | 2.00K | 4.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 96.00K | 51.00K | 141.00K | 89.76K | 198.00K | 12.61K | 11.00K | 8.00K | 0.00 | -794.00K | 3.00K | -195.00K | -489.00K | 0.00 | 238.00K | 300.00K | 59.00K | 133.00K | 33.00K | 20.00K | 32.00K | 21.00K | 20.00K | 25.00K | 1.00K | 1.00K |
| EBITDA | -17.14M | -15.34M | -26.34M | -27.93M | -7.58M | -7.81M | -8.24M | -7.28M | -8.61M | -3.56M | -283.00K | -653.00K | -778.00K | -3.03M | -516.00K | -1.24M | -2.49M | -2.15M | -2.18M | -1.48M | -1.95M | -2.35M | -2.39M | -2.33M | -553.00K | -271.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,433.33% | 0.00% | 948.78% | 0.00% | -921.43% | -1,348.91% | -3,890.63% | -531.60% | -1,879.31% | -1,491.92% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -17.98M | -14.59M | -27.37M | -28.03M | -7.77M | -7.82M | -8.25M | -7.29M | -8.61M | -2.76M | -286.00K | -458.00K | -289.00K | -3.03M | -754.00K | -1.54M | -2.55M | -2.29M | -2.21M | -1.50M | -1.98M | -2.37M | -2.41M | -2.35M | -554.00K | -272.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,533.33% | 0.00% | 352.44% | 0.00% | -1,346.43% | -1,675.00% | -3,982.81% | -564.44% | -1,907.76% | -1,512.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 742.00K | -811.00K | 717.00K | -312.00K | -73.00K | -8.67K | -9.00K | -9.00K | -18.00K | -808.00K | 3.00K | -195.00K | 0.00 | 0.00 | -4.00K | 31.00K | -37.00K | -8.00K | -10.00K | -5.00K | -8.00K | -2.00K | -4.00K | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -17.24M | -15.40M | -26.66M | -28.34M | -7.85M | -7.83M | -8.26M | -7.30M | -8.63M | -3.57M | -283.00K | -653.00K | -289.00K | 0.00 | -758.00K | -1.51M | -2.59M | -2.29M | -2.22M | -1.50M | -1.99M | -2.37M | -2.41M | -2.35M | -554.00K | -272.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,433.33% | 0.00% | 352.44% | 0.00% | -1,353.57% | -1,641.30% | -4,040.63% | -566.42% | -1,916.38% | -1,517.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 449.00K | 0.00 | -3.24M | -2.21M | -540.00K | -1.53M | -1.49M | -89.00K | 0.00 | -60.00K | -3.00K | 195.00K | 489.00K | 3.03M | -28.00K | -81.00K | -169.00K | -118.00K | -82.00K | -114.00K | -30.00K | -65.00K | -89.00K | -83.00K | 0.00 | 0.00 |
| Net Income | -17.69M | -15.40M | -23.42M | -26.13M | -7.31M | -6.30M | -6.77M | -7.21M | -8.63M | -3.51M | -280.00K | -848.00K | -778.00K | -3.03M | -730.00K | -1.43M | -2.42M | -2.18M | -2.14M | -1.39M | -1.96M | -2.31M | -2.33M | -2.27M | -554.00K | -272.00K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9,333.33% | 0.00% | 948.78% | 0.00% | -1,303.57% | -1,553.26% | -3,776.56% | -537.28% | -1,845.69% | -1,402.02% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | -0.15 | -0.24 | -0.27 | -0.05 | -0.10 | -0.13 | -0.15 | -0.19 | -0.31 | 0.00 | 0.00 | 0.00 | -0.10 | -0.05 | -0.24 | -0.52 | -0.01 | -0.01 | -0.01 | -0.02 | -0.06 | -0.09 | -0.09 | -0.02 | -0.01 |
| EPS Diluted | 0.00 | -0.15 | -0.24 | -0.27 | -0.05 | -0.10 | -0.13 | -0.15 | -0.19 | -0.31 | 0.00 | 0.00 | 0.00 | -0.10 | -0.05 | -0.24 | -0.52 | -0.01 | -0.01 | -0.01 | -0.02 | -0.06 | -0.09 | -0.09 | -0.02 | -0.01 |
| Weighted Avg Shares Out | 0.00 | 101.53M | 97.93M | 97.31M | 136.48M | 63.78M | 53.20M | 46.80M | 45.62M | 11.43M | 273.43M | 214.38M | 179.12M | 31.08M | 13.67M | 5.96M | 4.64M | 297.60M | 191.67M | 140.37M | 100.40M | 37.75M | 25.07M | 24.09M | 25.77M | 25.77M |
| Weighted Avg Shares Out (Dil) | 0.00 | 101.53M | 97.93M | 97.31M | 136.48M | 63.78M | 53.20M | 46.80M | 45.62M | 11.43M | 273.43M | 214.38M | 179.12M | 31.08M | 13.67M | 5.96M | 4.64M | 297.60M | 191.67M | 140.37M | 100.40M | 37.75M | 25.07M | 24.09M | 25.77M | 25.77M |
Tiziana Life Sciences Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer
NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce the appointment of Matthew Davis, MD,...
Tiziana Life Sciences finds promising indicator of MS treatment success
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced a significant update regarding non-active secondary progressive multiple sclerosis (SPMS) patients treated with h intranasal foralumab in the company's expanded access program. A reduction in microglial activation, which is associated with lowered inflammation in...
Tiziana Life Sciences Announces Reduction in Microglial Activation in a Total of 5 Out of 6 Intranasal Foralumab Expanded Access Patients with Non-Active Secondary Progressive Multiple Sclerosis
NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced a reduction in microglial activation as seen in...
Tiziana Life Sciences to Host KOL Webinar on Foralumab in Non-Active Secondary Progressive Multiple Sclerosis (SPMS)
NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced it will host a virtual KOL event to discuss...
Tiziana Life Sciences Announces Participation on the Webull Corporate Communications Service Platform
NEW YORK, May 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that they are now participating on the new...
Tiziana Life Sciences Announces Chief Medical Officer Invited to Give Presentation on Intranasal Foralumab on May 17
NEW YORK, May 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Medical Officer is presenting at...
Tiziana shares positive findings on intranasal foralumab in treating intracerebral hemorrhage
Tiziana Life Sciences Ltd (NASDAQ:TLSA) reported promising in-depth findings on the utility of its lead candidate, intranasal foralumab, which is the only fully human anti-CD3 monoclonal antibody (mAb), in the treatment of intracerebral hemorrhage (ICH), a subtype of stroke. The...
Tiziana Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference
NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced broad-based findings on the utility of nasal anti-CD3...
Tiziana Life Sciences provides update on development pipeline
Tiziana Life Sciences has updated investors on its lead programs in development along with the release of its financial results for the year ended December 31, 2022. The biotechnology company's interim CEO Gabriele Cerrone said that, after it announced in late...
Tiziana Life Sciences Ltd Reports Annual Results for the Twelve Months Ended December 31, 2022, and Corporate Update
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced financial results for the twelve months ended...
Source: https://incomestatements.info
Category: Stock Reports